Ken Griffin Cullinan Oncology, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$16.03 - $20.86 $104,195 - $135,590	6,500 Added 19.06%	40,600 $679,000
Q2 2024 Aug 14, 2024	BUY	$15.63 - $29.35 $336,045 - $631,025	21,500 Added 170.63%	34,100 $594,000
Q1 2024 May 15, 2024	BUY	$10.17 - $19.02 $44,748 - $83,688	4,400 Added 53.66%	12,600 $214,000
Q4 2023 Feb 14, 2024	BUY	$7.89 - $10.23 $11,835 - $15,345	1,500 Added 22.39%	8,200 $83,000
Q3 2023 Nov 14, 2023	BUY	$9.05 - $11.72 $32,580 - $42,192	3,600 Added 116.13%	6,700 $60,000
Q2 2023 Aug 14, 2023	BUY	$8.8 - $13.4 $2,640 - $4,020	300 Added 10.71%	3,100 $33,000
Q1 2023 May 15, 2023	BUY	$10.2 - $11.91 $16,319 - $19,056	1,600 Added 133.33%	2,800 $28,000
Q4 2022 Feb 14, 2023	SELL	$9.72 - $13.62 $244,944 - $343,224	-25,200 Reduced 95.45%	1,200 $12,000
Q3 2022 Nov 14, 2022	SELL	$11.82 - $15.42 $11,820 - $15,420	-1,000 Reduced 3.65%	26,400 $338,000

146

67.6M

612K

118K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $499M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.